AKOYA BIOSCIENCES INC (AKYA) Fundamental Analysis & Valuation

NASDAQ:AKYA • US00974H1041

Current stock price

1.29 USD
-0.07 (-5.15%)
At close:
1.2899 USD
0 (-0.01%)
After Hours:

This AKYA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AKYA Profitability Analysis

1.1 Basic Checks

  • In the past year AKYA has reported negative net income.
  • In the past year AKYA has reported a negative cash flow from operations.
  • AKYA had negative earnings in each of the past 5 years.
  • In the past 5 years AKYA always reported negative operating cash flow.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -42.20%, AKYA is not doing good in the industry: 80.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • With an excellent Gross Margin value of 61.74%, AKYA belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
  • AKYA's Gross Margin has been stable in the last couple of years.
  • AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AKYA Health Analysis

2.1 Basic Checks

  • AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AKYA has been increased compared to 1 year ago.
  • Compared to 5 years ago, AKYA has more shares outstanding
  • AKYA has a worse debt/assets ratio than last year.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • AKYA has an Altman-Z score of -4.23. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
  • AKYA has a Altman-Z score of -4.23. This is amonst the worse of the industry: AKYA underperforms 89.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.23
ROIC/WACCN/A
WACC12.42%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • AKYA has a Current Ratio of 0.61. This is a bad value and indicates that AKYA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.61, AKYA is not doing good in the industry: 98.21% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.40 indicates that AKYA may have some problems paying its short term obligations.
  • AKYA has a worse Quick ratio (0.40) than 96.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.4
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AKYA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.69% over the past year.
  • AKYA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.55%.
  • AKYA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.10% yearly.
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%

3.2 Future

  • AKYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.11% yearly.
  • AKYA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.53% yearly.
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. AKYA Valuation Analysis

4.1 Price/Earnings Ratio

  • AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • AKYA's earnings are expected to grow with 14.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.96%
EPS Next 3Y14.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKYA Dividend Analysis

5.1 Amount

  • AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AKYA Fundamentals: All Metrics, Ratios and Statistics

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (7/7/2025, 8:00:00 PM)

After market: 1.2899 0 (-0.01%)

1.29

-0.07 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12
Earnings (Next)08-04
Inst Owners34.48%
Inst Owner Change-100%
Ins Owners4.15%
Ins Owner Change0%
Market Cap64.44M
Revenue(TTM)79.96M
Net Income(TTM)-47.53M
Analysts50.91
Price Target1.45 (12.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.8%
Min EPS beat(2)-53.04%
Max EPS beat(2)-2.56%
EPS beat(4)1
Avg EPS beat(4)-13.87%
Min EPS beat(4)-53.04%
Max EPS beat(4)1.15%
EPS beat(8)3
Avg EPS beat(8)-8.79%
EPS beat(12)4
Avg EPS beat(12)-9.37%
EPS beat(16)5
Avg EPS beat(16)-10.77%
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-18.23%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-12.79%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)3
Avg Revenue beat(8)-9.2%
Revenue beat(12)7
Avg Revenue beat(12)-5.07%
Revenue beat(16)10
Avg Revenue beat(16)-2.97%
PT rev (1m)-24.7%
PT rev (3m)-54.86%
EPS NQ rev (1m)6.19%
EPS NQ rev (3m)-5.47%
EPS NY rev (1m)8.52%
EPS NY rev (3m)-6.25%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-6.21%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-5.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS1.6
BVpS-0.12
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.74%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.4
Altman-Z -4.23
F-Score5
WACC12.42%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%
EBIT growth 1Y35.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.58%
EBIT Next 3Y7.24%
EBIT Next 5Y9.43%
FCF growth 1Y48.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.89%
OCF growth 3YN/A
OCF growth 5YN/A

AKOYA BIOSCIENCES INC / AKYA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AKOYA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 1 / 10 to AKYA.


What is the valuation status of AKOYA BIOSCIENCES INC (AKYA) stock?

ChartMill assigns a valuation rating of 0 / 10 to AKOYA BIOSCIENCES INC (AKYA). This can be considered as Overvalued.


How profitable is AKOYA BIOSCIENCES INC (AKYA) stock?

AKOYA BIOSCIENCES INC (AKYA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AKOYA BIOSCIENCES INC?

The Earnings per Share (EPS) of AKOYA BIOSCIENCES INC (AKYA) is expected to grow by 38.62% in the next year.